Dr. Roberto Diaz graduated summa cum laude from Manhattanville College with a degree in chemistry. He earned his MS, PhD, and MD degrees from New York University School of Medicine where he completed the medical scientist training program with an emphasis on molecular oncology. After graduating, he spent his first year of residency in Internal Medicine at Yale University’s Griffin Hospital. At Griffin, he was voted best first-year resident by the nursing staff. He then completed his training in Radiation Oncology at Vanderbilt University where he served as chief resident in his final year.
Dr. Diaz is board certified in Radiation Oncology and is the Breast Section Chief in the Department of Radiation Oncology at Moffitt Cancer Center. His current academic appointment is Associate Professor at the University of South Florida, Tampa, FL, in the Department of Oncologic Sciences, College of Medicine. His professional memberships include the American Society for Radiation Oncology (ASTRO), the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the Radiological Society of North America (RSNA), Christian Medical and Dental Associations (CMDA), and the Latin American Association of Radiation Oncology (ALATRO).
Dr. Diaz has research interests both in translational and clinical breast cancer. His research has included discovery of biomarkers for metastatic breast cancer, targeted drug delivery, and novel radiosensitizers in Phase I clinical trials. During his time as a Holman Pathway resident at Vanderbilt, he was awarded grants from the Department of Defense, ASTRO, and the RSNA. For his work, he has won numerous national awards including the Resident Basic Science Research Award from ASTRO and the RSNA Roentgen Resident/Fellow Research Award .
Dr. Diaz has authored and co-authored over 30 scientific articles for publication in international and national peer-reviewed journals like Nature Medicine and Cancer Research. In addition, Dr. Diaz has presented at numerous international and national research meetings, including at the European Society for Radiotherapy & Oncology (ESTRO), as well as annual meetings of ASTRO and AACR. He has been invited as a visiting professor to the Republic of Macedonia to conduct training of local physicians in oncology and to improve their national breast cancer screening and treatment guidelines. Dr. Diaz has participated in televised interviews with CNN en Español as well as Univisión Tampa, on topics ranging from the effects of radiation on humans to cancer screening recommendations for women: https://www.youtube.com/watch?v=eppKgV2_Lsk
One of his greatest passions is medical missions. Dr. Diaz has worked in prisons in Ecuador and Peru; villages in Honduras and El Salvador; as well as in Port-au-Prince, Haiti. One of his greatest joys is mentoring students and resident physicians. Dr. Diaz’s past mentees have gone on to successful careers in medicine and research with numerous publications and honors in the fields of radiation oncology and cancer biology.
Originally from the Dominican Republic, Dr. Diaz is fluent in both Spanish and English. Prior to working at Moffitt Cancer Center, he has lived in Santo Domingo, Manhattan, Atlanta and Nashville.
Education & Training
Vaderbilt University Medical Center - Radiation Oncology
Griffin Hospital, Yale University - Internal Medicine
CLINICAL TRIAL 18356
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Mills M, Liveringhouse C, Lee F, Nanda RH, Ahmed KA, Washington IR, Thapa R, Fridley BL, Blumencranz P, Extermann M, Loftus L, Balducci L, Diaz R. The prevalence of luminal B subtype is higher in older postmenopausal women with ER+/HER2- breast cancer and is associated with inferior outcomes. Geriatr Oncol. 2021 Mar.12(2):219-226. Pubmedid: 32859560. Pmcid: PMC7907245.
Dohm A, Diaz R, Nanda RH. The Role of Radiation Therapy in the Older Patient. Curr Oncol Rep. 2021 Jan.23(1):11. Pubmedid: 33387104.
Yu JB, Brock KK, Campbell AM, Chen AL, Diaz R, Escorcia F, Gupta G, Hrinivich WT, Joseph S, Korpics M, Onderdonk BE, Pandit-Taskar N, Wood B, Woodward WA. Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop. Int J Radiat Oncol Biol Phys. 2020 Nov.108(3):539-545. Pubmedid: 32434040.
Mills MN, Russo NW, Nanda RH, Wilson JP, Altoos TA, Caldwell DL, Stout LL, Dube S, Blumencranz PW, Allen KG, Diaz R. Management of ductal carcinoma in situ with accelerated partial breast irradiation brachytherapy: Implications for guideline expansion. Brachytherapy. 2020 Dec.20(2):345-352. Pubmedid: 33317964.
Broman K, Sun W, Zhou JM, Fridley B, Diaz R, Laronga C. Outcomes of selective whole breast irradiation following lumpectomy with intraoperative radiation therapy for hormone receptor positive breast cancer. Am J Surg. 2019 Oct.218(4):749-754. Pubmedid: 31345502. Pmcid: PMC7810130.
Figura NB, Rizk VT, Mohammadi H, Evernden B, Mokhtari S, Yu HM, Robinson TJ, Etame AB, Tran ND, Liu J, Washington I, Diaz R, Czerniecki BJ, Soliman H, Han HS, Sahebjam S, Forsyth PA, Ahmed KA. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res Treat. 2019 Jun.175(3):781-788. Pubmedid: 30859348.
Chowdhary M, Lee A, Gao S, Wang D, Barry PN, Diaz R, Bagadiya NR, Park HS, Yu JB, Wilson LD, Moran MS, Higgins SA, Knowlton CA, Patel KR. Is Proton Therapy a "Pro" for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database. Front Oncol. 2019 Jan.8:678. Pubmedid: 30693271. Pmcid: PMC6339938.
Ahmed KA, Liveringhouse CL, Mills MN, Figura NB, Grass GD, Washington IR, Harris EE, Czerniecki BJ, Blumencranz PW, Eschrich SA, Scott JG, Diaz R, Torres-Roca JF. Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management. EBioMedicine. 2019 Aug.47:163-169. Pubmedid: 31416721. Pmcid: PMC6796536.
Small W, Thomas TO, Alvarado M, Baum M, Bulsara M, Diaz R, Donnelly E, Feldman S, Grobmyer S, Hoefer R, Joseph D, Kang S, Laronga C, McKee A, Rosen B, Tobias J, Uhl V, Vaidya JS, Wenz F, Holmes D. Commentary on "Accelerated partial breast irradiation consensus statement: Update of an ASTRO Evidence-Based Consensus Statement". Pract Radiat Oncol. 2018 Mar.7(3):e159-e163. Pubmedid: 28363492.
B Figura N, Long W, Yu M, Robinson TJ, Mokhtari S, Etame AB, Tran ND, Diaz R, Soliman H, S Han H, Sahebjam S, Forsyth PA, Ahmed KA. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat. 2018 Jun.169(2):391-396. Pubmedid: 29392582.
Ahmed KA, Grass GD, Orman AG, Liveringhouse C, Montejo ME, Soliman HH, Han HS, Czerniecki BJ, Torres-Roca JF, Diaz R. Personalizing Radiation Treatment Delivery in the Management of Breast Cancer. Int J Breast Cancer. 2018 Jun.2018:6729802. Pubmedid: 29984003. Pmcid: PMC6015692.
Mills MN, Yang GQ, Oliver DE, Liveringhouse CL, Ahmed KA, Orman AG, Laronga C, Hoover SJ, Khakpour N, Costa RLB, Diaz R. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis. Eur J Cancer. 2018 Jul.98:48-58. Pubmedid: 29870876.
Yun JH, Diaz R, Orman AG. Breast Reconstruction and Radiation Therapy. Cancer Control. 2018 Jan.25(1). Pubmedid: 30132338. Pmcid: PMC6108018.
Ryckman JM, Shelton JW, Waller AF, Schreibmann E, Latifi K, Diaz R. Anatomic structure-based deformable image registration of brachytherapy implants in the treatment of locally advanced cervix cancer. Brachytherapy. 2017 Jul.15(5):584-592. Pubmedid: 27263057.
Mellon EA, Orman A, Joya LE, Montejo ME, Laronga C, Hoover SJ, Lee MC, Khakpour N, Kubal PF, Diaz R. Frequency of whole breast radiation therapy after intraoperative radiation therapy due to criteria identified by lumpectomy. Brachytherapy. 2017 Jul.16(1):174-180. Pubmedid: 27816540.
Dossett LA, Abbott AM, Sun W, Loftus L, Lee MC, Diaz R, Laronga C. Factors predictive of failure to complete planned intraoperative breast radiation using the intrabeam® system. J Surg Oncol. 2016 Dec.114(8):930-932. Pubmedid: 27861907.
Nagaraju GP, Alese OB, Landry J, Diaz R, El-Rayes BF. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. Oncotarget. 2014 Oct.5(20):9980-9991. Pubmedid: 25296971. Pmcid: PMC4259452.
Patel K, Wen J, Magliocca K, Muller S, Liu Y, Chen ZG, Saba N, Diaz R. Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation. Cancer Chemother Pharmacol. 2014 Nov.74(5):1015-1022. Pubmedid: 25205430.
Corso CD, Jarrio C, Nunnery EW, Ali AN, Ghavidel S, Rossi PJ, Diaz R. Dosimetric and cost comparison of first fraction imaging versus fractional re-imaging on critical organ dose in vaginal cuff brachytherapy. Pract Radiat Oncol. 2014 Mar.3(4):256-262. Pubmedid: 24674395.
Vlacich G, Spratt DE, Diaz R, Phillips JG, Crass J, Li CI, Shyr Y, Cmelak AJ. Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer. Radiother Oncol. 2014 Mar.110(3):435-440. Pubmedid: 24440043.
Nagaraju GP, Ganji PN, Park W, Wen J, Mahaseth H, Landry J, Farris AB, Willingham F, Sullivan PS, Proia DA, El-Hariry I, Taliaferro-Smith L, Diaz R, El-Rayes BF. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3. Angiogenesis. 2013 Oct.16(4):903-917. Pubmedid: 23838996.
Vlacich G, Diaz R, Thorpe SW, Murphy BA, Kirby W, Sinard RJ, Shakhtour B, Shyr Y, Murphy P, Netterville JL, Yarbrough WG, Cmelak AJ. Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy. Oncologist. 2013 Jan.17(5):673-681. Pubmedid: 22550060. Pmcid: PMC3360907.
Okwan-Duodu D, Umpierrez GE, Brawley OW, Diaz R. Obesity-driven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages. Am J Cancer Res. 2013 Jan.3(1):21-33. Pubmedid: 23359288. Pmcid: PMC3555202.
Nagaraju GP, Zhu S, Wen J, Farris AB, Adsay VN, Diaz R, Snyder JP, Mamoru S, El-Rayes BF. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Lett. 2013 Dec.341(2):195-203. Pubmedid: 23933177.
Okwan-Duodu D, Landry J, Shen XZ, Diaz R. Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis. Am J Physiol Regul Integr Comp Physiol. 2013 Aug.305(3):R205-R215. Pubmedid: 23739345.
Nagaraju GP, Aliya S, Zafar SF, Basha R, Diaz R, El-Rayes BF. The impact of curcumin on breast cancer. Integr Biol (Camb). 2012 Sep.4(9):996-1007. Pubmedid: 22772921.
Ali AN, Diaz R, Shu HK, Paulino AC, Esiashvili N. A Surveillance, Epidemiology and End Results (SEER) program comparison of adult and pediatric Wilms' tumor. Cancer. 2012 May.118(9):2541-2551. Pubmedid: 21918969.
Amin M, Gabram S, Bumpers H, Landry J, Jani AB, Diaz R, Rizzo M. Feasibility of accelerated partial breast irradiation in a large inner-city public hospital. Ann Surg Oncol. 2012 Dec.19(13):4094-4098. Pubmedid: 22732836.
Corso CD, Ali AN, Diaz R. Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res. 2011 Oct.1(3):390-412. Pubmedid: 21969260. Pmcid: PMC3180059.
Lopez-Barcons LA, Ali AN, Diaz R. Application of recombinant and non-recombinant peptides in the determination of tumor response to cancer therapy. Curr Pharm Biotechnol. 2011 Feb.12(2):320-335. Pubmedid: 21050162.
Diaz R, Jaboin JJ, Morales-Paliza M, Koehler E, Phillips JG, Stinson S, Gilbert J, Chung CH, Murphy BA, Yarbrough WG, Murphy PB, Shyr Y, Cmelak AJ. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010 Jun.77(2):468-476. Pubmedid: 19577867.
Passarella RJ, Spratt DE, van der Ende AE, Phillips JG, Wu H, Sathiyakumar V, Zhou L, Hallahan DE, Harth E, Diaz R. Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. Cancer Res. 2010 Jun.70(11):4550-4559. Pubmedid: 20484031. Pmcid: PMC2880200.
Spratt DE, Diaz R, McElmurray J, Csiki I, Duggan D, Lu B, Delbeke D. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer. Clin Nucl Med. 2010 Apr.35(4):237-243. Pubmedid: 20305410.
Passarella RJ, Zhou L, Phillips JG, Wu H, Hallahan DE, Diaz R. Recombinant peptides as biomarkers for tumor response to molecular targeted therapy. Clin Cancer Res. 2009 Oct.15(20):6421-6429. Pubmedid: 19825959. Pmcid: PMC2763341.
Diaz R, Blakey MD, Murphy PB, Cryar AK, Cmelak AJ. Thyroid storm after intensity-modulated radiation therapy: a case report and discussion. Oncologist. 2009 Mar.14(3):233-239. Pubmedid: 19286762.
Diaz R, Passarella RJ, Hallahan DE. Determining glioma response to radiation therapy using recombinant peptides. Expert Rev Anticancer Ther. 2008 Nov.8(11):1787-1796. Pubmedid: 18983239.
Han Z, Fu A, Wang H, Diaz R, Geng L, Onishko H, Hallahan DE. Noninvasive assessment of cancer response to therapy. Nat Med. 2008 Mar.14(3):343-349. Pubmedid: 18297085.
Albert JM, Gonzalez A, Massion PP, Chen H, Olson SJ, Shyr Y, Diaz R, Lambright ES, Sandler A, Carbone DP, Putnam JB, Johnson DH, Lu B. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2007 Sep.16(9):1845-1851. Pubmedid: 17855704.
Diaz R, Lue J, Mathews J, Yoon A, Ahn D, Garcia-España A, Leonardi P, Vargas MP, Pellicer A. Inhibition of Ras oncogenic activity by Ras protooncogenes. Int J Cancer. 2005 Jan.113(2):241-248. Pubmedid: 15386411.
Diaz R, Lopez-Barcons L, Ahn D, Garcia-Espana A, Yoon A, Matthews J, Mangues R, Perez-Soler R, Pellicer A. Complex effects of Ras proto-oncogenes in tumorigenesis. Carcinogenesis. 2004 Apr.25(4):535-539. Pubmedid: 14633661.
Hernández-Muñoz I, Benet M, Calero M, Jiménez M, Díaz R, Pellicer A. rgr oncogene: activation by elimination of translational controls and mislocalization. Cancer Res. 2003 Jul.63(14):4188-4195. Pubmedid: 12874025.
Pérez de Castro I, Diaz R, Malumbres M, Hernández MI, Jagirdar J, Jiménez M, Ahn D, Pellicer A. Mice deficient for N-ras: impaired antiviral immune response and T-cell function. Cancer Res. 2003 Apr.63(7):1615-1622. Pubmedid: 12670913.
Diaz R, Ahn D, Lopez-Barcons L, Malumbres M, Perez de Castro I, Lue J, Ferrer-Miralles N, Mangues R, Tsong J, Garcia R, Perez-Soler R, Pellicer A. The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res. 2002 Aug.62(15):4514-4518. Pubmedid: 12154063.
Leonardi P, Kassin E, Hernandez-Muñoz I, Diaz R, Inghirami G, Pellicer A. Human rgr: transforming activity and alteration in T-cell malignancies. Oncogene. 2002 Aug.21(33):5108-5116. Pubmedid: 12140761.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub